{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:02:23Z","timestamp":1760522543072,"version":"3.33.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1097\/ftd.0b013e318058a2c2","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T04:34:53Z","timestamp":1180067693000},"page":"319-324","source":"Crossref","is-referenced-by-count":14,"title":["A Novel Enantioselective Microassay for the High-Performance Liquid Chromatography Determination of Oxcarbazepine and Its Active Metabolite Monohydroxycarbazepine in Human Plasma"],"prefix":"10.1097","volume":"29","author":[{"given":"Iolanda","family":"Mazzucchelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Franco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Fattore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Marchiselli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Perucca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20210129","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2165\/00023210-200418010-00006","article-title":"Spotlight on oxcarbazepine in epilepsy.","volume":"18","author":"Bang","year":"2004","journal-title":"CNS Drugs"},{"key":"R2-9-20210129","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2165\/00003088-200342120-00002","article-title":"Clinical pharmacokinetics of oxcarbazepine.","volume":"42","author":"May","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"R3-9-20210129","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00003088-200038030-00001","article-title":"Is there a role for therapeutic drug monitoring of new anticonvulsants?","volume":"38","author":"Perucca","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"R4-9-20210129","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1021\/jm980627g","article-title":"Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives.","volume":"42","author":"Benes","year":"1999","journal-title":"J Med Chem"},{"key":"R5-9-20210129","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/cp.1999.v66.103170001","article-title":"Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects.","volume":"66","author":"Volosov","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"R6-9-20210129","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1528-1167.2006.00459.x","article-title":"Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and puerperium.","volume":"47","author":"Mazzucchelli","year":"2006","journal-title":"Epilepsia"},{"key":"R7-9-20210129","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0378-4347(85)80136-5","article-title":"Gas chromatographic assay for oxcarbazepine and its main metabolites in plasma.","volume":"345","author":"von Unruh","year":"1985","journal-title":"J Chromatog"},{"key":"R8-9-20210129","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/bms.1200131203","article-title":"Gas chromatographic\/mass spectrometric assays for oxcarbazepine and its main metabolites, 10-hydroxy-carbazepine and carbazepine-10,11-trans-diol.","volume":"13","author":"von Unruh","year":"1986","journal-title":"Biomed Environ Mass Spectrom"},{"key":"R9-9-20210129","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/jat\/28.6.509","article-title":"Hydroxycarbazepine distribution in three postmortem cases.","volume":"28","author":"Levine","year":"2004","journal-title":"J Anal Toxicol"},{"key":"R10-9-20210129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1600-0404.1983.tb05340.x","article-title":"Pharmacokinetics of 10-OH-carbazepine, the main metabolite of the antiepileptic oxcarbazepine, from serum and saliva concentrations.","volume":"68","author":"Kristensen","year":"1983","journal-title":"Acta Neurol Scand"},{"key":"R11-9-20210129","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0378-4347(00)84360-1","article-title":"Determination of oxcarbazepine in human plasma by high-performance liquid chromatography.","volume":"275","author":"Menge","year":"1983","journal-title":"J Chromatogr"},{"key":"R12-9-20210129","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0378-4347(00)84455-2","article-title":"Quantitative determination of oxcarbazepine.","volume":"274","author":"Norfalise","year":"1983","journal-title":"J Chromatogr"},{"key":"R13-9-20210129","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0378-4347(00)82406-8","article-title":"Simple and rapid micro-analytical high-performance liquid chromatographic technique for the assay of oxcarbazepine and its primary active metabolite 10-hydroxycarbazepine.","volume":"528","author":"Elyas","year":"1990","journal-title":"J Chromatogr"},{"key":"R14-9-20210129","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/bdd.2510110405","article-title":"Oxcarbazepine disposition: preliminary observations in patients.","volume":"11","author":"Kumps","year":"1990","journal-title":"Biopharm Drug Dispos"},{"key":"R15-9-20210129","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/bmc.1130050507","article-title":"Solid phase extraction of oxcarbazepine and its metabolites from plasma for analysis by high performance liquid chromatography.","volume":"5","author":"Hartley","year":"1991","journal-title":"Biomed Chromatogr"},{"key":"R16-9-20210129","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0378-4347(92)80459-4","article-title":"Determination of the R-() and S-(+) enantiomers of the monohydroxymetabolite of oxcarbazepine in human serum by enantioselective high-performance liquid chromatography.","volume":"581","author":"Flesch","year":"1992","journal-title":"J Chromatogr"},{"key":"R17-9-20210129","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0378-4347(94)00217-7","article-title":"Automated microanalysis of oxcarbazepine and its monohydroxy and transdiol metabolites in plasma by liquid chromatography.","volume":"658","author":"Rouan","year":"1994","journal-title":"J Chromatogr B Biomed Appl"},{"key":"R18-9-20210129","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-2710.1995.tb00654.x","article-title":"Rapid micromethod for simultaneous measurement of oxcarbazepine and its active metabolite in plasma by high-performance liquid chromatography.","volume":"20","author":"Matar","year":"1995","journal-title":"J Clin Pharm Ther"},{"key":"R19-9-20210129","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1080\/10826079508009293","article-title":"Stereoselective bioanalysis of oxcarbazepine and the enantiomers of its metabolites by high-performance liquid chromatography.","volume":"18","author":"Pichini","year":"1995","journal-title":"J Liq Chromatogr"},{"key":"R20-9-20210129","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0378-4347(95)00246-F","article-title":"Improved detection and determination of carbamazepine and oxcarbazepine and their metabolites by high-performance liquid chromatography.","volume":"673","author":"Pienimaki","year":"1995","journal-title":"J Chromatogr B Biomed Appl"},{"key":"R21-9-20210129","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1600-0404.1996.tb00016.x","article-title":"Fluctuations of 10-hydroxy-carbazepine during the day in epileptic patients.","volume":"93","author":"May","year":"1996","journal-title":"Acta Neurol Scand"},{"key":"R22-9-20210129","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0378-4347(99)00531-9","article-title":"Simultaneous stereoselective high-performance liquid chromatographic determination of 10-hydroxycarbazepine and its metabolite carbamazepine-10,11-trans-dihydrodiol in human urine.","volume":"738","author":"Volosov","year":"2000","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"R23-9-20210129","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0378-4347(01)00289-4","article-title":"Development of a high throughput 96-well plate sample preparation method for the determination of trileptal (oxcarbazepine) and its metabolites in human plasma.","volume":"762","author":"Souppart","year":"2001","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"R24-9-20210129","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0731-7085(01)00684-7","article-title":"LC determination of oxcarbazepine and its active metabolite in human serum.","volume":"28","author":"Levert","year":"2002","journal-title":"J Pharm Biomed Anal"},{"key":"R25-9-20210129","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/jms.325","article-title":"Validated assay for quantification of oxcarbazepine and its active dihydro metabolite 10-hydroxycarbazepine in plasma by atmospheric pressure chemical ionization liquid chromatography\/mass spectrometry.","volume":"37","author":"Maurer","year":"2002","journal-title":"J Mass Spectrom"},{"key":"R26-9-20210129","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1570-0232(02)00664-5","article-title":"Liquid chromatographic determination of oxcarbazepine and its metabolites in plasma of epileptic patients after solid-phase extraction.","volume":"783","author":"Mandrioli","year":"2003","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R27-9-20210129","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jchromb.2005.09.019","article-title":"Liquid chromatography-electrospray mass spectrometry determination of carbamazepine, oxcarbazepine and eight of their metabolites in human plasma.","volume":"828","author":"Breton","year":"2005","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R28-9-20210129","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jchromb.2005.09.009","article-title":"Simultaneous liquid chromatographic determination of lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in plasma of patients with epilepsy.","volume":"828","author":"Contin","year":"2005","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R29-9-20210129","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.phrs.2004.09.008","article-title":"A simple method to monitor plasma concentrations of oxcarbazepine, carbamazepine, their main metabolites and lamotrigine in epileptic patients.","volume":"51","author":"Franceschi","year":"2005","journal-title":"Pharmacol Res"},{"key":"R30-9-20210129","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jchromb.2005.02.004","article-title":"Determination of oxcarbazepine and its metabolites in postmortem blood and hair by means of liquid chromatography with mass detection (HPLC\/APCI\/MS).","volume":"825","author":"Klys","year":"2005","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R31-9-20210129","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/chromsci\/44.1.45","article-title":"Drug monitoring and toxicology: a procedure for the monitoring of oxcarbazepine metabolite by HPLC-UV.","volume":"44","author":"Juenke","year":"2006","journal-title":"J Chromatogr Sci"},{"key":"R32-9-20210129","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1517\/14656566.7.4.401","article-title":"Anticonvulsants in the treatment of bipolar mania.","volume":"7","author":"Goodnick","year":"2006","journal-title":"Exp Opin Pharmacother"},{"key":"R33-9-20210129","first-page":"1","article-title":"Non-epilepsy uses of antiepilepsy drugs.","volume":"58","author":"Zaremba","year":"2006","journal-title":"Pharmacol Rep"},{"key":"R34-9-20210129","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1684\/j.1950-6945.2004.tb00053.x","article-title":"Antiepileptic drugs: indications other than epilepsy.","volume":"6","author":"Spina","year":"2004","journal-title":"Epileptic Disorders"},{"key":"R35-9-20210129","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1586\/14737175.6.3.429","article-title":"Drug therapy of trigeminal neuralgia.","volume":"6","author":"Canavero","year":"2006","journal-title":"Expert Rev Neurother"},{"key":"R36-9-20210129","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.eplepsyres.2006.01.011","article-title":"Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcarbazepine therapy.","volume":"69","author":"Striano","year":"2006","journal-title":"Epilepsy Res"},{"key":"R37-9-20210129","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00003088-200645040-00002","article-title":"Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age.","volume":"45","author":"Perucca","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"R38-9-20210129","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2125.1993.tb00378.x","article-title":"The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid.","volume":"36","author":"Tartara","year":"1993","journal-title":"Br J Clin Pharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e318058a2c2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T17:05:09Z","timestamp":1737047109000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-200706000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e318058a2c2","relation":{},"ISSN":["0163-4356"],"issn-type":[{"type":"print","value":"0163-4356"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}